|
19 Sep 2019 |
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
|
|
19 Sep 2019 |
PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial
|
|
19 Sep 2019 |
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
|
|
19 Sep 2019 |
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)
|
|
19 Sep 2019 |
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
|
|
19 Sep 2019 |
Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia
|
|
19 Sep 2019 |
Y-Trap Enters Collaboration with Merck KGaA, Darmstadt, Germany, to Develop Novel Antibody-Ligand Traps for Immuno-Oncology
|
|
19 Sep 2019 |
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
|
|
18 Sep 2019 |
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
|
18 Sep 2019 |
STORM Therapeutics Presents Breakthrough Data Showing in Vivo Efficacy and Therapeutic Proof of Concept for Targeting RNA Modifying Enzymes
|
|
18 Sep 2019 |
Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform
|
|
18 Sep 2019 |
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
|
|
18 Sep 2019 |
Procarta receives CARB-X award of up to $9.2 million
|
|
18 Sep 2019 |
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
|
|
18 Sep 2019 |
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist
|
|
18 Sep 2019 |
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis
|
|
18 Sep 2019 |
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
|
|
18 Sep 2019 |
Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels
|
|
18 Sep 2019 |
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
|
|
18 Sep 2019 |
FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
|
